Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity
| dc.contributor.author | Peters, Hannah Louise | |
| dc.contributor.author | Jochmans, Dirk | |
| dc.contributor.author | de Wilde, Adriaan H. | |
| dc.contributor.author | Posthuma, Clara C. | |
| dc.contributor.author | Snijder, Eric J. | |
| dc.contributor.author | Neyts, Johan | |
| dc.contributor.author | Seley-Radtke, Katherine | |
| dc.date.accessioned | 2025-07-30T19:22:41Z | |
| dc.date.issued | 2015-06-10 | |
| dc.description.abstract | A series of doubly flexible nucleoside analogues were designed based on the acyclic sugar scaffold of acyclovir and the flex-base moiety found in the fleximers. The target compounds were evaluated for their antiviral potential and found to inhibit several coronaviruses. Significantly, compound 2 displayed selective antiviral activity (CC₅₀ >3× EC₅₀) towards human coronavirus (HCoV)-NL63 and Middle East respiratory syndrome-coronavirus, but not severe acute respiratory syndrome-coronavirus. In the case of HCoV-NL63 the activity was highly promising with an EC₅₀ <10 μM and a CC₅₀ >100 μM. As such, these doubly flexible nucleoside analogues are viewed as a novel new class of drug candidates with potential for potent inhibition of coronaviruses. | |
| dc.description.sponsorship | We thank Jessika Zevenhoven-Dobbe for technical assistance. This work was funded in part by the National Institutes of Health [R21AI097685 (K.S.R.) and T32GM066706 (K.S.R. and H.L.P.)], and the EU FP7 project SILVER (260644, D.J., J.N., A.dW., C.C.P., and E.J.S.). | |
| dc.description.uri | https://pmc.ncbi.nlm.nih.gov/articles/PMC4466200/ | |
| dc.format.extent | 4 pages | |
| dc.genre | journal articles | |
| dc.identifier | doi:10.13016/m2dpvv-agvr | |
| dc.identifier.citation | Peters, Hannah L., Dirk Jochmans, Adriaan H. de Wilde, Clara C. Posthuma, Eric J. Snijder, Johan Neyts, and Katherine L. Seley-Radtke. “Design, Synthesis and Evaluation of a Series of Acyclic Fleximer Nucleoside Analogues with Anti-Coronavirus Activity.” Bioorganic & Medicinal Chemistry Letters 25, no. 15 (August 1, 2015): 2923–26. https://doi.org/10.1016/j.bmcl.2015.05.039. | |
| dc.identifier.uri | https://doi.org/10.1016/j.bmcl.2015.05.039 | |
| dc.identifier.uri | http://hdl.handle.net/11603/39586 | |
| dc.language.iso | en_US | |
| dc.publisher | Elsevier | |
| dc.relation.isAvailableAt | The University of Maryland, Baltimore County (UMBC) | |
| dc.relation.ispartof | UMBC Student Collection | |
| dc.relation.ispartof | UMBC Faculty Collection | |
| dc.relation.ispartof | UMBC Chemistry & Biochemistry Department | |
| dc.rights | This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author. | |
| dc.subject | Coronaviruses | |
| dc.subject | SARS | |
| dc.subject | Nucleosides | |
| dc.subject | Fleximers | |
| dc.subject | Acyclovir | |
| dc.subject | Antiviral | |
| dc.subject | MERS-CoV | |
| dc.title | Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity | |
| dc.type | Text | |
| dcterms.creator | https://orcid.org/0000-0002-0154-3459 |
